AU729546B2 - Topical formulations containing as a therapeutic active agent fatty acids or fatty alcohols or monoglyceride derivatives thereof for treating of mucosa infections - Google Patents

Topical formulations containing as a therapeutic active agent fatty acids or fatty alcohols or monoglyceride derivatives thereof for treating of mucosa infections Download PDF

Info

Publication number
AU729546B2
AU729546B2 AU49411/97A AU4941197A AU729546B2 AU 729546 B2 AU729546 B2 AU 729546B2 AU 49411/97 A AU49411/97 A AU 49411/97A AU 4941197 A AU4941197 A AU 4941197A AU 729546 B2 AU729546 B2 AU 729546B2
Authority
AU
Australia
Prior art keywords
lipid
formulation
titre
concentration
incubated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU49411/97A
Other languages
English (en)
Other versions
AU4941197A (en
Inventor
Thordis Kristmundsdottir
Halldor Thormar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LipoMedica ehf
Original Assignee
LipoMedica ehf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LipoMedica ehf filed Critical LipoMedica ehf
Publication of AU4941197A publication Critical patent/AU4941197A/en
Assigned to LIPOMEDICA EHF. reassignment LIPOMEDICA EHF. Alteration of Name(s) of Applicant(s) under S113 Assignors: KRISTMUNDSDOTTIR, THORDIS, THORMAR, HALLDOR
Application granted granted Critical
Publication of AU729546B2 publication Critical patent/AU729546B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU49411/97A 1996-11-14 1997-11-14 Topical formulations containing as a therapeutic active agent fatty acids or fatty alcohols or monoglyceride derivatives thereof for treating of mucosa infections Ceased AU729546B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IS4386 1996-11-14
IS4386 1996-11-14
PCT/DK1997/000524 WO1998020872A1 (en) 1996-11-14 1997-11-14 Topical formulations containing as a therapeutic active agent fatty acids or fatty alcohols or monoglyceride derivatives thereof for treating of mucosa infections

Publications (2)

Publication Number Publication Date
AU4941197A AU4941197A (en) 1998-06-03
AU729546B2 true AU729546B2 (en) 2001-02-01

Family

ID=36699955

Family Applications (1)

Application Number Title Priority Date Filing Date
AU49411/97A Ceased AU729546B2 (en) 1996-11-14 1997-11-14 Topical formulations containing as a therapeutic active agent fatty acids or fatty alcohols or monoglyceride derivatives thereof for treating of mucosa infections

Country Status (10)

Country Link
US (1) US6596763B1 (enExample)
EP (1) EP0941087B1 (enExample)
JP (1) JP2001504461A (enExample)
AP (1) AP1209A (enExample)
AT (1) ATE442844T1 (enExample)
AU (1) AU729546B2 (enExample)
CA (1) CA2271843A1 (enExample)
DE (1) DE69739583D1 (enExample)
IS (1) IS5051A (enExample)
WO (1) WO1998020872A1 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19648545B4 (de) † 1996-11-25 2009-05-07 Ceramtec Ag Monolithischer Vielschichtaktor mit Außenelektroden
ES2202872T3 (es) 1997-06-20 2004-04-01 Prometics Bodycare Limited Composicion protectora de la piel.
US6096332A (en) * 1998-06-30 2000-08-01 Mcneil-Ppc, Inc. Adding pharmaceutically active compounds to substrates
RU2186563C2 (ru) * 2000-02-25 2002-08-10 Государственное унитарное предприятие Тихоокеанский научно-исследовательский рыбохозяйственный центр Средство для лечения ожоговой раны
IL137559A (en) * 2000-07-27 2006-12-31 Amnon Sintov A system for administering drugs through the skin
AU2002221412B2 (en) * 2000-12-05 2006-04-13 Alexander Macgregor Hydrostatic delivery system for controlled delivery of agent
DE10156794B4 (de) * 2001-11-19 2006-05-18 Medigene Ag Arzneimittel zur Behandlung von Warzen
EP2055300B1 (de) 2001-11-19 2016-01-27 Medigene AG Arzneimittel enthaltend Isopropylmyristat und ein Catechin
US20050032896A1 (en) * 2002-06-21 2005-02-10 Liisa Neumann Use of synthetic retinoic acid in form of 13-cis vitamin A for treatment of autism
US20050095281A1 (en) * 2003-03-14 2005-05-05 Optime Therapeutics, Inc. Liposomal formulations and methods of use
ES2237298B1 (es) 2003-07-16 2006-11-01 Italfarmaco, S.A. Formulaciones mucoadhesivas semisolidas.
GB0317999D0 (en) * 2003-07-31 2003-09-03 Univ Liege Improvements in or relating to drug delivery systems
US20050058673A1 (en) 2003-09-09 2005-03-17 3M Innovative Properties Company Antimicrobial compositions and methods
KR101232924B1 (ko) * 2003-09-09 2013-02-13 쓰리엠 이노베이티브 프로퍼티즈 컴파니 농축된 항균 조성물 및 방법
WO2005037300A1 (en) * 2003-10-09 2005-04-28 Medigene Ag The use of a polyphenol for the treatment of a cancerous or pre-cancerous lesion of the skin
US20050079235A1 (en) * 2003-10-09 2005-04-14 Eggert Stockfleth Use of a polyphenol for the treatment of actinic keratosis
US20070276049A1 (en) * 2003-11-11 2007-11-29 Schlievert Patrick M Regulation of Cell Membrane-Mediated Effects
US8796332B2 (en) 2004-08-03 2014-08-05 Regents Of The University Of Minnesota Compositions and methods for controlling infections
CA2578404A1 (en) * 2004-08-23 2006-03-02 Auckland Uniservices Limited Gastric therapies and compositions therefor
US8535709B2 (en) * 2004-12-13 2013-09-17 Southeastern Medical Technologies, Llc Agents for controlling biological fluids and methods of use thereof
ES2411054T3 (es) * 2004-12-17 2013-07-04 Halldor Thormar Emulsiones antibacterianas concentradas estables de monocaprina en agua
TW200719884A (en) 2005-03-10 2007-06-01 3M Innovative Properties Co Methods of treating ear infections
WO2006099359A2 (en) 2005-03-10 2006-09-21 3M Innovative Properties Company Methods of reducing microbial contamination
CA2598985A1 (en) * 2005-03-10 2006-09-21 3M Innovative Properties Company Antimicrobial pet wipes and methods
US20060229364A1 (en) * 2005-03-10 2006-10-12 3M Innovative Properties Company Antiviral compositions and methods of use
MX2007010908A (es) 2005-03-10 2007-12-05 3M Innovative Properties Co Composiciones antimicrobianas que comprenden esteres de acidos hidroxicarboxilicos.
US20080075793A1 (en) * 2006-09-21 2008-03-27 Dunshee Wayne K Antiviral compositions and methods of use
DK2060192T3 (en) * 2007-10-17 2016-02-22 Wild Gmbh & Co Kg Rudolf Composition comprising lemon balm extracts
JP2009155257A (ja) * 2007-12-26 2009-07-16 Taiyo Corp 抗菌剤及びそれを含有する口腔用組成物並びに飲食品
ES2344673B1 (es) 2008-08-07 2011-05-03 Italfarmaco, S.A. Uso de estriol en la preparacion de una formulacion farmaceutica parael tratamiento de atrofia vaginal en mujeres con riesgo de potologiatumoral.
ES2344675B1 (es) 2008-12-19 2011-04-28 Italfarmaco, S.A. Uso de estriol en la preparacion de una formulacion farrmaceutica para el tratamiento de atrofia vaginal en mujeres con riesgo de patologiacardiovascular.
DE102009008094A1 (de) 2009-02-09 2010-08-19 Barnikol-Keuten, Doris, Dr. In situ Haft-Gelbildende Zubereitungen, insbesondere zur topischen Anwendung auf befeuchtete Haut/Schleimhaut
RU2516279C2 (ru) 2009-08-06 2014-05-20 Анитокс Корпорейшн Консервант для воды и корма
JP5864429B2 (ja) 2009-11-09 2016-02-17 スポットライト テクノロジー パートナーズ エルエルシーＳｐｏｔｌｉｇｈｔ Ｔｅｃｈｎｏｌｏｇｙ Ｐａｒｔｎｅｒｓ Ｌｌｃ 架橋ヒドロゲル組成物、ヒドロゲル組成物の形成方法、及びキット
AU2010314994B2 (en) 2009-11-09 2016-10-06 Spotlight Technology Partners Llc Fragmented hydrogels
PH12013500117B1 (en) 2010-08-27 2019-07-17 Anitox Corp Antimicrobial formulation
WO2012035751A1 (ja) * 2010-09-14 2012-03-22 日油株式会社 除菌洗浄剤組成物
JP5749915B2 (ja) * 2010-11-02 2015-07-15 花王株式会社 オートインデューサー−２阻害剤
US20130261146A1 (en) * 2010-12-09 2013-10-03 The Research Foundation Of State University Of New York Nitric oxide and its biomedical significance
CA2832490C (en) 2011-04-13 2016-06-21 Biosafe Technologies, Inc. Compositions for internal and external insecticides, ovicides, repellents and wound healing
CA2848777A1 (en) 2011-10-20 2013-04-25 Anitox Corporation Antimicrobial formulations with pelargonic acid
JP2015504312A (ja) 2011-11-30 2015-02-12 アニトックス コーポレーション アルデヒド、有機酸及び有機酸エステルの抗微生物混合物
WO2017221276A1 (en) * 2016-06-20 2017-12-28 Capretto Ehf. Synergistic effects, augmenting antimicrobial effects of lipids
US20200069630A1 (en) * 2016-07-11 2020-03-05 Hennipen Life Sciences, Llc Compositions for sexually transmitted diseases
JP6754030B2 (ja) * 2017-04-20 2020-09-09 マイクロアルジェコーポレーション株式会社 モノアシルグリセロール、抗菌剤、及びモノアシルグリセロールの製造方法
US11246872B2 (en) 2019-06-14 2022-02-15 Propella Therapeutics, Inc. Topical acyclovir formulations and uses thereof
US11572342B2 (en) 2020-09-18 2023-02-07 Niche Biopharmaceuticals LLC Antimicrobial and antiviral sulfur containing glycerol monoester derivatives

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4406884A (en) * 1981-06-23 1983-09-27 The Procter & Gamble Company Topical antimicrobial composition
US4520132A (en) * 1982-09-27 1985-05-28 Pennwalt Corporation Use of undecylenic acid to treat herpes labialis
AU566647B2 (en) * 1982-09-30 1987-10-29 Union Carbide Corporation Curable epoxy resin molding composition
US5208257A (en) 1986-04-21 1993-05-04 Kabara Jon J Topical antimicrobial pharmaceutical compositions and methods
US5434182A (en) * 1987-12-31 1995-07-18 Isaacs; Charles E. Antibacterial fatty acid compositions
US5342625A (en) 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
NZ250714A (en) * 1990-10-30 1996-05-28 Mcneil Ppc Inc Liquid composition comprising esters of higher fatty acids for use as a vaginal douche and to prevent toxic shock toxin production
IL104283A (en) * 1992-12-30 1996-12-05 Agis Ind 1983 Ltd Non-emulsion antiviral topical pharmaceutical composition comprising acyclovir an aqueous gel agent and an alkali oleate
IL110380A0 (en) 1994-07-20 1994-10-21 Agis Ind 1983 Ltd Antiviral topical pharmaceutical compositions
DK1001759T3 (da) 1996-09-17 2005-10-10 Avanir Pharmaceuticals Virusinhibering med langkædede alkoholer, alkaner, fedtsyrer og amider

Also Published As

Publication number Publication date
EP0941087B1 (en) 2009-09-16
AU4941197A (en) 1998-06-03
ATE442844T1 (de) 2009-10-15
DE69739583D1 (de) 2009-10-29
US6596763B1 (en) 2003-07-22
WO1998020872A1 (en) 1998-05-22
IS5051A (is) 1999-05-12
CA2271843A1 (en) 1998-05-22
JP2001504461A (ja) 2001-04-03
AP1209A (en) 2003-09-30
EP0941087A1 (en) 1999-09-15

Similar Documents

Publication Publication Date Title
US6596763B1 (en) Topical formulations containing as a therapeutic active agent fatty acids or fatty alcohols or monoglyceride derivatives thereof for treating of mucosa infections
Kristmundsdóttir et al. Development and evaluation of microbicidal hydrogels containing monoglyceride as the active ingredient
CN1177594C (zh) 预防治疗粘膜皮肤各种感染 (特别是包括人类免疫缺陷病毒的性传播性疾病 )、炎症、赘生物或其他类型疾病的方法和制剂
US5545401A (en) Antiviral, spermicidal vaginal gel and foam containing low molecular weight povidone-iodine
CN100488517C (zh) 捕获和灭活病原性微生物和精子的组合物及其制药用途
EP1030547B1 (en) Methods for preventing and treating bacterial infections using cellulose acetate phthalate or hydroxypropyl methylcellulose phthalate excipients
Thormar et al. Hydrogels containing monocaprin have potent microbicidal activities against sexually transmitted viruses and bacteria in vitro.
KR20060118443A (ko) 항미생물성 조성물 및 방법
Neyts et al. Hydrogels containing monocaprin prevent intravaginal and intracutaneous infections with HSV‐2 in mice: Impact on the search for vaginal microbicides
US7226914B2 (en) Cellulose sulfate and other sulfated polysaccharides to prevent and treat papilloma virus infection and other infections
ES2550815T3 (es) Composiciones antimicrobianas acuosas que contienen carragenanos
EP0303516B1 (en) Topically active compositions of double-stranded RNAs
US20110159091A1 (en) Rapidly dispersible vaginal tablet that provides a bioadhesive gel
US20120260922A1 (en) Topical use of hydroxytyrosol and derivatives for the prevention of hiv infection
JP5322918B2 (ja) 避妊用組成物
US20050043402A1 (en) Methods and formulations for counteracting infection of mucosa or skin
Bourinbaiar et al. Anti-HIV effect of gramicidin in vitro: potential for spermicide use
Gagné et al. Protective effect of a thermoreversible gel against the toxicity of nonoxynol-9
KR20040094855A (ko) 국소용 살균제 및 피임제로서의 수라민 또는 그 유도체
JPS6379816A (ja) 局所用法のための組成物
JP2019527240A (ja) 脂質の抗微生物効果を増大する相乗効果
US5380523A (en) High energy coprecipitate of nonoxynol oligomer, PVP and iodine having contraceptive and potent anti-HIV properties
US20030003095A1 (en) Activated carbon for preventing pregnancy and sexually transmitted disease
Thorgeirsdóttir et al. Effects of polysorbates on antiviral and antibacterial activity of monoglyceride in pharmaceutical formulations
CA2897038C (en) Microbicidal composition comprising an octoxynol and a quinolizidine alkaloid compound or a source thereof

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: LIPOMEDICA EHF.

Free format text: THE FORMER OWNER WAS: HALLDOR THORMAR, THORDIS KRISTMUNDSDOTTIR

FGA Letters patent sealed or granted (standard patent)